WCLC 2026 | Leads Biolabs’ Opamtistomig (LBL-024) Oral Presentation Demonstrates Robust Response and PFS Benefits in First‑Line NSCLC

Data ReadoutpositiveopamtistomigPositive

AI Analysis

Summary

Leads Biolabs presented updated Phase II data for opamtistomig (LBL-024), a PD-L1/4-1BB bispecific antibody, showing robust response and progression-free survival benefits in first-line NSCLC treatment at the 2026 World Conference on Lung Cancer.

Clinical Trial Data

Phase

Phase II

Primary Endpoint

Met

Outcome Details

Updated Phase II data demonstrated robust response and PFS benefits

Importance:6/10

Sentiment:

0.70

oncologylung cancerimmunotherapybispecific antibodyPD-L1conference presentationNSCLC

Related Companies

$CHHE $TRAX $WHEN

Read the original article

Published by GlobeNewswire Clinical Studies on September 14, 2026 9:59 AM

Read Original